Pushing drug-eluting stents into uncharted territory: Simpler than you think - More complex than you imagine

Circulation

Volumn 113, Issue 19, 2006, Pages 2262-2265

  Rogers, Campbell ^a,b   Edelman, Elazer R ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

Author keywords

Editorials; Failure; Registries; Restenosis; Stents

Indexed keywords

CORONARY STENT; DRUG ELUTING STENT; EDITORIAL; EVIDENCE BASED MEDICINE; HEART MUSCLE REVASCULARIZATION; HUMAN; IN-STENT RESTENOSIS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSTHESIS FAILURE; THROMBOSIS; BLOOD VESSEL PROSTHESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY OBSTRUCTION; EQUIPMENT; METHODOLOGY; NOTE; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; RISK FACTOR; STENT;

CARDIOVASCULAR AGENT;

BLOOD VESSEL PROSTHESIS; CARDIOVASCULAR AGENTS; CORONARY RESTENOSIS; CORONARY STENOSIS; EQUIPMENT FAILURE; HUMANS; MYOCARDIAL REVASCULARIZATION; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; STENTS;

EID: 33744994739     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.106.623470     Document Type: Editorial

References (22)

1. Emerson RW. The Writer in Representative Men: Seven Lectures. New York: Modern Library; 2004.
2. Edelman ER, Rogers C. Stent vs stent equivalency trials: are some stents more equal than others? Circulation. 1999;100:896-898.
3. Hausleiter J, Kastrati A, Mehilli J, Schuhlen H, Pache J, Dotzer F, Sattelberger U, Dirschinger J, Schomig A. Impact of lesion complexity on the capacity of a trial to detect differences in stent performance: results from the ISAR-STEREO trial. Am Heart J. 2003;146:882-886.
4. Rogers C, Edelman ER. Endovascular stent design dictates experimental restenosis and thrombosis. Circulation. 1995;91:2995-3001.
5. Rogers C. Clinical perspectives on drug and design differences. Rev Cardiovasc Med. 2005;6:S3-S12.
6. Levin A, Jonas M, Hwang C, Edelman ER. Local and systemic drug competition in drug-eluting stent tissue deposition properties. J Control Release. 2005;109:236-243.
7. Levin AD, Vukmirovic N, Hwang CW, Edelman ER. Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel. Proc Natl Acad Sci. 2004;101:9463-9467.
8. Serruys PW, Kutryk MJB, Ong ATL. Coronary artery stents. N Engl J Med. 2006;354:483-495.
9. Goethe JW. Quoted in: Johann Wolfgang Goethe, Gedenkausgabe der Werke, Briefe und Gesproche [Johann Wolfgang Goethe, Collected Works, Letters and Conversations]. Beutler E, ed. Vol. 9. Zurich, Switzerland: Artemis-Verlag; 1962:651.
10. Charles Mingus, as quoted by his wife, Sue Mingus, and confirmed by telephone conversation between Sue Mingus and Elazer Edelman. Also available at: http://www.startliving.org.uk/2005/11/charles-mingus-quote.html. Accessed on May 2, 2006.
11. de Lezo JS, Medina A, Pan M, Romero M, Delgado A, Segura J, Hernandez E, Pavlovic D, Ojeda S, Fernandez-Duenas J, Ariza J, Mellan F. Drug-eluting stent for complex lesions: latest angiographic data from the randomized rapamycin versus paclitaxel CORPAL study. J Am Coll Cardiol. 2005;45:75A-76A. Abstract.
12. Dibra A, Kastrati A, Mehilli J, Pache J, Schühlen H, von Beckerath N, Ulm K, Wessely R, Dirschinger J, Schömig A. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med. 2005;353:663-670.
13. Goy J-J, Stauffer J-C, Siegenthaler S, Benoît A, Seydoux C. A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology: the TAXi trial. J Am Coll Cardiol. 2005;45:308-311.
14. Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J, Schühlen H, Schmitt C, Dirschinger J, Schömig A. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA. 2005;293:165-171.
15. Windecker S, Remondino A, Eberli FR, Jüni P, Räber L, Wenaweser P, Togni M, Billinger M, Tüller D, Seiler C, Roffi M, Corti R, Sütsch G, Maier W, Lüscher T, Hess OM, Egger M, Meier B. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med. 2005;353:653-662.
16. Mehilli J, Dibra A, Kastrati A, Pache J, Dirschinger J, Schömig A. Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. Eur Heart J. 2006;27:260-266.
17. Morice M-C, Colombo A, Meier B, Serruys P, Tamburino C, Guagliumi G, Sousa E, Stoll H-P. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial. JAMA. 2006;295:895-904.
18. Kastrati A, Dibra A, Mehilli J, Mayer S, Pinieck S, Pache J, Dirschinger J, Schömig A. Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents. Circulation. 2006;113:2293-2300.
19. Cutlip DE, Baim DS, Ho KKL, Popma JJ, Lansky AJ, Cohen DJ, Carrozza JP, Chauhan MS, Rodriguez O, Kuntz RE. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation. 2001;103:1967-1971.
20. Lemos PA, Hoye A, Goedhart D, Arampatzis CA, Saia F, van der Giessen WJ, McFadden E, Sianos G, Smits PC, Hofma SH, de Feyter PJ, van Domburg RT, Serruys PW. Clinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients: an evaluation from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) study. Circulation. 2004;109:1366-1370.
21. Jonas M, Edelman ER, Groothuis A, Baker AB, Seifert P, Rogers C. Vascular neointimal formation and signaling pathway activation in response to stent injury in insulin resistant and diabetic animal models. Circ Res. 2005;97:725-733.
22. Maimonides M. Chapter 24. In: The Guide of the Perplexed. Pines S, trans. Vol. 2, Book III. Chicago, Ill: University of Chicago Press; 1963:497.